From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours

  • Emilio Bajetta | emilio.bajetta@istitutotumori.mi.it Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, Milan, Italy.
  • Giuseppe Procopio Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, Milan, Italy.
  • Sara Pusceddu Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, Milan, Italy.
  • Filippo Pietrantonio Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, Milan, Italy.
  • Massimo Milione Pathology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Marco Maccauro Nuclear Medicine Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Elena Verzoni Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, Milan, Italy.
  • Valentina Guadalupi Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, Milan, Italy.
  • Marco Platania Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, Milan, Italy.

Abstract

Neuroendocrine tumours (NETs) represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. Diagnosis of neuroendocrine tumours relies upon histological examination augmented by newer techniques, such as pet-dotatoc scan. Surgery represents the only curative therapeutic approach. In advanced unresectable disease, medical treatment is the best choice. Somatostatin analogues allow adequate control of the carcinoid syndrome with a low effect on tumour cell growth. Chemotherapy has a good activity only in poor prognosis patients. According to the clinical course of the disease, a multimodal approach could be evaluated in selected cases. New target therapy including multikinase inhibitors, monoclonal antibody and m-tor inhibitors is now under clinical investigation for the treatment of advanced NETs. Preliminary results demonstrated a good activity in terms of disease control rate and tumour shrinkage.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2011-12-14
Info
Issue
Section
Reviews
Keywords:
Neuroendocrine tumours - Angiogenesis - Metastasis - Chemotherapy - Target therapy
Statistics
  • Abstract views: 1393

  • FULL TEXT: 158
How to Cite
Bajetta, E., Procopio, G., Pusceddu, S., Pietrantonio, F., Milione, M., Maccauro, M., Verzoni, E., Guadalupi, V., & Platania, M. (2011). From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours. Oncology Reviews, 3(2), 79-87. https://doi.org/10.4081/oncol.2009.81